权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Miami Clinical and Translational Science Institute

迈阿密临床与转化科学研究所

基本信息

批准号：
10708431
负责人：
Olveen Carrasquillo
金额：
$ 399.1万
依托单位：
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-18 至 2030-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10708431
关键词：
Acceleration Address Adoption Advocate Area Behavior Therapy Biomedical Research Clinical Clinical Research Clinical Sciences Collaborations Communities Community Health Complex County Cultural Diversity Development Devices Disparity Dissemination and Implementation Education Effectiveness Ensure Equity Ethnic Origin Federally Qualified Health Center Florida Future Goals Health Health Benefit Health Promotion Healthcare Systems Hispanic Immigrant Inequity Interdisciplinary Study International Intervention Knowledge acquisition Language Leadership Medical Mentors Methods Minority Minority-Serving Institution Participant Patients Persons Pharmaceutical Preparations Population Positioning Attribute Procedures Process Public Hospitals Puerto Rico Race Reporting Research Research Personnel Research Project Grants Resources Risk Factors Safety Science Services Shapes Stigmatization System Testing Training Training Programs Translational Research Universities Work career development clinical translation community organizations disorder risk effective therapy effectiveness evaluation effectiveness research equity, diversity, and inclusion ethnic minority experience health disparity health equity health equity promotion implementation efforts improved innovation member metropolitan multidisciplinary novel programs racial minority recruit research study response skills socioeconomic disadvantage successful intervention tool translational scientist

项目摘要

Project Summary Located in South Florida (SoFL), the goals of University of Miami’s Clinical and Translational Science Institute (CTSI) are to improve the health of our community, address health disparities, and promote health equity. The CTSI accomplishes these goals by catalyzing the development, demonstration, and dissemination of scientific and operational innovations that improve the efficiency, effectiveness, and quality of clinical and translational research. This is done through bidirectional engagement of diverse stakeholders, including patient advocates and community collaborators, to help identify gaps, challenges, and chokepoints in the translational research process. In response, the CTSI develops and test stakeholder-driven resources, tools, and interventions ultimately promoting the adoption and integration of those that are demonstrated to be successful, through dissemination and implementation efforts. This work is shaped by three primary factors: 1) SoFL is characterized by complex and multifaceted diversity with respect to race, ethnicity, language, immigrant status, socioeconomic disadvantage, and stigmatization. This complexity allows CTSI Hub investigators to explore research questions difficult to conceptualize and evaluate elsewhere; 2) CTSI prioritizes diversity, equity, inclusion, and accessibility (DEIA) in its scientific workforce and research participants; and 3) CTSI has a strong, successful and sustained record of authentic community and stakeholder engagement which facilitates multidisciplinary research that can successfully overcome the translational pitfall of replicating existing inequities. The CTSI’s focus, scope of activities and aims are grounded in an understanding of these factors and their complex interplay with one another. Together with diverse stakeholders, the CTSI will: 1) support the development and dissemination of innovative resources and services to increase the quality, efficiency, and effectiveness of research across the entire translational research spectrum; 2) promote research collaborations aimed at facilitating and accelerating research to improve community health, address health disparities, and promote health equity; 3) develop innovative training programs to support a team science-oriented CTS workforce, from translational scientists to clinical research professionals and key stakeholders; and 4) support CTS research responsive to these overarching goals. Through these efforts, the CTSI expects to achieve significant improvements in the quality, safety, efficiency, effectiveness, and informativeness of its Clinical and Translational Enterprise. The CTSI will then broadly disseminate its acquired knowledge regionally and nationally to maximize impact and opportunity, both now and in the future. By doing so, the CTSI accelerates bringing the benefits of translational science (more effective treatments, drugs, devices, behavioral interventions, and medical procedures) to all people, regardless of their identity or access. PHS 398/2590 (Rev. 06/09) Page Continuation Format Page

项目总结